Genmab A/S
Genmab A/S
GMAB
Valuace
70
Růst
30
Zdraví
78
Cena
$ 29.05
Dnes
--1.60 (-4.73%)
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
17.9B
Obrat
9B
Zisk
3B
Aktiva
41B
Dluh
1B
ROE
0%
ROA
0%
PE
6
PS
2
Cena 1R
17-35
⌀ Cena
25.88
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
10-Q
Celoroční 10-K
8-K
Nadcházející oznámení zisků
17-02-2026
Poslední dividenda

Profil

Genmab A/S vyvíjí protilátkovou terapii pro léčbu rakoviny a dalších onemocnění především v Dánsku. Společnost prodává DARZALEX, lidskou monoklonální protilátku k léčbě pacientů s mnohočetným myelomem (MM); teprotumumab k léčbě onemocnění štítné žlázy; ofatumurnab, lidskou monoklonální protilátku k léčbě chronické lymfatické leukémie (CLL) a roztroušené sklerózy; a Amivantamab k léčbě pokročilého nebo metastazujícího karcinomu žaludku nebo jícnu a NSCLC. Mezi jeho produkty patří daratumumab pro léčbu MM, non-MM rakoviny krve a AL amyloidózy; GEN1047; tisotumab vedotin pro léčbu cervikálních, ovariálních a solidních nádorů; DuoBody-PD-L1x4-1BB a DuoBody-CD40x4-1BB pro léčbu solidních nádorů; Epcoritamab pro relabující/refrakterní difúzní velké B-buněčné lymfomy a chronické lymfatické leukémie; a HexaBody-CD38 a DuoBody CD37 k léčbě hematologických malignit. Společnost také vyvíjí produkty, které ve fázi 2 zahrnují Teclistamab pro vazookluzivní krize; Camidanlumab tesirin pro léčbu hodgkinského lymfomu a solidních nádorů; JNJ-64007957 a JNJ-64407564 pro léčbu MM; PRV-015 pro léčbu celiakie; Mim8 pro léčbu hemofilie A a Lu AF82422 pro léčbu mnohočetné atrofie. Kromě toho má přibližně 20 aktivních preklinických programů. Společnost má komerční licenci a smlouvu o spolupráci se společností Seagen Inc. na vývoj tisotumab vedotin. Má také dohodu o spolupráci se společností CureVac AG na výzkumu a vývoji diferencovaných protilátek na bázi mRNA; AbbVie na vývoji epcoritamabu; a spolupráci se společnostmi BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS a Bolt Biotherapeutics, Inc. Genmab A/S byla založena v roce 1999 a sídlí v Kodani v Dánsku.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
2638
Založení
2009-06-01
Adresa
Kalvebod Brygge 43
CEO
Jan G.J. van de Winkel

Podobné společnosti

Zahraniční články

Výsledovka

Rozvaha

Peněžní toky

Výsledovka

Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
Revenue TTM 2025202420232022202120202019201820172016201520142013201220112010
Total Revenues8,653.63,722.921,526.016,474.014,595.08,482.010,111.05,366.03,025.12,365.41,816.11,133.0850.4663.6484.6350.9582.1
Cost of Revenues542.0309.2985.0226.00.00.00.00.00.00.00.00.00.00.00.0532.5582.5
Gross Profit8,111.63,413.720,541.016,248.014,595.08,482.010,111.05,366.03,025.12,365.41,816.11,133.0850.4663.6484.6-181.6-0.4
Revenue 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Total Revenues1,054.81,022.05,861.7715.06,441.05,540.0779.0603.04,678.04,744.0
Cost of Revenues80.858.0361.242.0337.0273.028.027.0126.0100.0
Gross Profit974.1964.05,500.5673.06,104.05,267.0751.0576.04,552.04,644.0
Operating Income TTM 2025202420232022202120202019201820172016201520142013201220112010
R&D Expenses0.00.00.07,630.05,562.04,181.03,137.02,386.01,431.2874.3660.9487.7505.7527.6536.70.00.0
Selling General & Admin Expenses0.00.00.03,297.02,676.01,283.0661.0342.0213.7147.0102.491.279.566.764.667.9160.3
Depreciation & Amortization135.471.1413.0240.0686.0445.0443.0259.087.669.841.031.812.311.715.115.021.0
Total Operating Expenses4,941.02,162.713,838.010,927.08,238.05,464.03,798.02,728.01,644.91,021.3763.3402.7585.2594.3601.367.9160.3
Operating Income3,170.61,251.06,703.05,321.06,357.03,018.06,313.02,638.01,380.31,344.21,052.8730.4265.269.3-116.7-249.4-160.7
Operating Income TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
R&D Expenses0.00.00.00.00.00.00.00.01,948.02,088.0
Selling General & Admin Expenses0.00.00.00.00.00.00.00.0934.0839.0
Depreciation & Amortization0.018.0101.416.088.085.014.013.060.081.0
Total Operating Expenses731.8505.03,219.2485.03,944.03,165.0515.0460.02,882.02,927.0
Operating Income242.3459.02,281.3188.02,160.02,102.0236.0116.01,670.01,717.0
Net Income TTM 2025202420232022202120202019201820172016201520142013201220112010
Interest Income271.3138.1995.0939.0324.0197.0184.0120.062.941.432.637.338.328.617.83.51.4
Interest Expense108.961.0120.027.021.013.010.07.00.42.80.20.14.13.32.743.139.6
Other Expense290.8-46.02,461.0316.0678.0965.0-409.0221.0231.7-280.577.427.132.2-3.92.639.638.2
IBT3,461.41,204.99,164.05,637.07,035.03,983.05,904.02,859.01,612.01,063.71,130.2757.5297.365.4-114.1-209.8-122.4
Income Tax Expense705.2241.21,320.01,285.01,513.0975.01,146.0693.0139.8-39.8-56.9-6.0-4.0-4.8-2.65.920.9
Net Income2,756.1963.87,844.04,352.05,522.03,008.04,758.02,166.01,472.11,103.61,187.1763.5301.3112.4-487.1-596.4-321.5
Net Income TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Interest Income47.932.0158.433.0224.0162.0292.046.0295.0243.0
Interest Expense43.93.057.05.054.018.019.04.06.08.0
Other Expense-187.423.0399.256.01,442.0-383.071.0133.0-744.0985.0
IBT54.8482.02,680.6244.03,602.01,719.0307.0249.0926.02,702.0
Income Tax Expense23.981.0551.349.0-243.0453.0104.057.0286.0573.0
Net Income30.9401.02,129.2195.03,845.01,266.0203.0192.0640.02,129.0
Per Share Data TTM 2025202420232022202120202019201820172016201520142013201220112010
EPS$0.00$0.00$0.00$66.02$8.45$4.60$7.30$3.44$2.40$1.81$1.98$1.31$0.54$0.22$-1.06$-1.33$-0.72
EPS Diluted$0.00$0.00$0.00$66.02$8.37$4.55$7.22$3.40$2.37$1.78$1.92$1.26$0.53$0.22$-1.06$-1.33$-0.72
Shares Outstanding616.2621.5646.365.9653.9654.0651.8629.6612.7608.3598.8585.2563.2509.8460.4449.1449.1
Diluted Shares Outstanding672.6626.9646.365.9660.1660.5658.9636.4620.5620.9617.7607.7572.5519.1460.4449.1449.1
Per Share Data TTM 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
EPS$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.98$3.26
EPS Diluted$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.97$3.23
Shares Outstanding616.2616.0617.6637.3641.6648.9648.9653.0653.1653.1
Diluted Shares Outstanding672.6620.7619.9639.3641.5648.9648.9656.6657.9658.7
Current Assets TTM 202420232022202120202019201820172016201520142013201220112010
Cash And Equivalents4,331.09,858.014,867.09,893.08,957.07,260.03,552.0532.91,347.5307.0874.0359.1168.167.065.2101.0
Short Term Investments11,402.011,243.013,268.012,431.010,381.08,819.07,419.05,573.24,075.23,614.92,619.22,301.41,388.81,436.81,035.41,548.3
Total Cash & ST Investments15,733.021,101.028,135.022,324.019,338.016,079.010,971.06,106.15,422.73,922.03,493.22,660.51,557.01,503.71,100.61,649.3
Accounts Receivable6,168.06,691.04,947.06,053.03,398.02,712.02,990.01,326.9636.7975.7174.7105.8136.0136.70.00.0
Inventory36.062.057.00.00.00.0-10,398.00.00.00.00.00.00.00.00.00.0
Other Current Assets0.00.00.00.00.00.010,398.00.00.00.00.00.00.013.4416.2770.1
Total Current Assets21,937.027,854.033,139.028,377.022,736.018,791.013,961.07,433.06,059.44,897.63,667.92,766.41,693.01,653.81,516.82,419.4
Current Assets 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Cash And Equivalents8,237.111,181.99,858.06,342.04,331.014,670.014,867.014,273.010,874.012,288.0
Short Term Investments10,188.311,099.111,243.010,976.011,402.014,914.013,268.013,252.014,010.012,256.0
Total Cash & ST Investments18,425.522,281.021,101.017,318.015,733.029,584.028,135.027,525.024,884.024,544.0
Accounts Receivable6,343.15,518.56,691.06,310.06,168.04,679.04,947.05,432.04,690.03,199.0
Inventory82.682.962.071.036.0106.057.070.051.0-488.0
Other Current Assets0.00.00.00.00.00.00.00.00.00.0
Total Current Assets24,851.227,882.327,854.023,699.021,937.034,369.033,139.033,027.029,749.028,231.0
Long-Term Assets TTM 202420232022202120202019201820172016201520142013201220112010
Net Property, Plant & Equipment1,880.01,891.01,641.01,322.0975.0736.0414.0161.5113.432.228.825.722.726.032.441.4
Goodwill2,518.02,535.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Intangible Assets12,011.012,343.0101.0146.0254.0338.0470.0470.4124.4181.9192.662.52.50.00.00.0
Long-Term Investments273.0280.0134.0133.0371.01,081.0149.00.00.00.00.00.00.00.00.0-1,547.9
Other Long-Term Assets12,011.00.0274.048.027.020.011.09.68.81.56.96.46.29.49.81,555.5
Total Long-Term Assets16,682.017,957.02,150.01,901.01,891.02,352.01,183.01,028.0543.5340.6234.7100.338.539.147.662.2
Total Assets38,619.045,811.035,289.030,278.024,627.021,143.015,144.08,461.06,602.95,238.23,902.52,866.71,731.51,692.91,564.42,481.6
Long-Term Assets 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Net Property, Plant & Equipment1,760.61,871.71,891.01,801.01,880.01,860.01,641.01,651.01,634.01,596.0
Goodwill2,256.32,451.92,535.02,407.02,518.00.00.00.00.00.0
Intangible Assets11,135.412,128.212,343.011,504.012,011.023.0101.0115.0129.0132.0
Long-Term Investments273.3262.5280.0249.0273.0216.0196.0156.0183.0140.0
Other Long-Term Assets0.00.00.00.00.00.00.037.031.043.0
Total Long-Term Assets16,232.717,605.217,957.015,961.016,682.02,311.02,150.02,211.02,229.02,163.0
Total Assets41,083.945,487.545,811.039,660.038,619.036,680.035,289.035,238.031,978.030,394.0
Current Liabilities TTM 202420232022202120202019201820172016201520142013201220112010
Accounts Payable3,400.03,482.00.00.0350.00.00.00.00.022.332.00.00.079.833.532.8
Short-Term Debt94.092.090.074.062.042.026.00.00.061.60.10.22.13.85.8121.9
Other Current Liabilities837.00.02,307.01,716.01,130.01,185.0912.0443.3176.599.599.6105.587.99.763.668.1
Current Liabilities4,364.05,308.02,484.01,823.01,568.01,253.0938.0443.3327.1411.5414.4656.0907.51,183.7976.71,324.6
Current Liabilities 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Accounts Payable3,603.73,501.73,482.03,182.03,400.02,512.00.00.01,878.01,833.0
Short-Term Debt101.796.792.091.094.092.090.083.082.089.0
Other Current Liabilities214.21,352.60.00.00.00.02,307.02,341.00.00.0
Current Liabilities3,997.85,221.55,308.04,585.04,364.02,759.02,484.02,902.01,993.01,955.0
Long-Term Liabilities TTM 202420232022202120202019201820172016201520142013201220112010
Long-Term Debt925.0937.0680.0523.0363.0277.0155.00.00.00.00.00.10.41.96.111.8
Capital Leases925.01,029.0770.0597.0425.0319.0181.00.00.00.00.10.42.55.711.817.9
Def. Tax Liability1,853.02,359.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Total Liabilities7,650.09,114.03,679.02,837.02,431.02,022.01,096.0446.6330.8411.5415.8833.71,072.01,309.71,078.01,401.5
Long-Term Liabilities 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Long-Term Debt839.0891.0937.0896.0925.0918.0680.0710.0721.0740.0
Capital Leases148.0143.01,029.0987.01,019.01,010.0680.0793.0803.0829.0
Def. Tax Liability2,097.42,279.22,359.01,762.01,853.00.00.00.00.00.0
Total Liabilities7,385.48,909.69,114.07,738.07,650.04,183.03,679.04,126.03,223.03,204.0
Total Common Equity TTM 202420232022202120202019201820172016201520142013201220112010
Common Stock66.066.066.066.066.066.065.061.561.260.459.557.051.850.344.944.9
Retained Earnings18,133.023,551.019,023.014,968.010,020.07,107.02,130.0-197.5-1,854.7-3,106.1-4,228.3-5,028.4-5,357.4-5,481.3-5,006.2-4,429.9
Comprehensive Income234.0490.060.098.081.054.098.091.782.1102.994.584.177.280.3-147.8-136.8
Total Common Equity30,969.036,697.031,610.027,441.022,196.019,121.014,048.08,014.46,272.24,826.73,486.72,032.9659.5383.2486.41,080.1
Total Common Equity 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Common Stock63.669.166.066.066.066.066.066.066.066.0
Retained Earnings22,868.224,429.023,551.019,623.018,133.019,803.019,023.018,452.016,165.014,666.0
Comprehensive Income-1,334.7-1,471.1490.0-346.0234.0108.060.0142.0112.0117.0
Total Common Equity33,698.536,577.936,697.031,922.030,969.032,497.031,610.031,112.028,755.027,190.0
Other TTM 202420232022202120202019201820172016201520142013201220112010
Total Debt1,019.01,029.0770.0597.0425.0319.0181.00.00.00.00.10.42.55.711.8133.7
Book Value30,969.036,697.031,610.027,441.022,196.019,121.014,048.08,014.46,272.24,826.73,486.72,032.9659.5383.2486.41,080.1
Other 2-20251-20254-20243-20242-20241-20244-20233-20232-20231-2023
Total Debt0.00.00.00.00.00.00.00.00.00.0
Book Value33,698.536,577.936,697.031,922.030,969.032,497.031,610.031,112.028,755.027,190.0
Cash Flow From Operating Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Net Income6,075.0963.87,844.05,637.07,035.03,983.05,904.02,859.01,612.01,063.71,130.2757.5297.3107.6-489.7-590.4-300.6
Depreciation & Amortization382.071.1413.0295.0362.0248.0259.0139.087.669.841.031.812.311.715.115.021.0
Stock-Based Compensation664.00.0721.0586.0439.0310.0200.0147.090.876.053.236.627.711.612.00.00.0
Change Working Capital-249.0225.2-1,595.01,362.0-1,930.0-770.0987.0-1,218.0-634.4239.6-858.9-538.4-221.8-240.2175.5-203.0378.4
Change In Accounts Receivable-252.0-166.1-1,590.0797.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Change In Accounts Payable-740.0400.30.0622.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Change In Inventories-36.0-9.0-5.0-57.00.00.00.00.00.00.00.00.00.00.00.0-1.535.3
Other Non-cash Items909.0-73.1388.0-622.0-1,994.0-997.0409.0-216.0-231.7280.5-77.4-27.1-32.23.8-2.6341.2169.3
Cash from Operations6,735.00.00.07,380.03,912.02,228.06,433.01,326.01,014.81,589.0327.7311.4132.7-128.070.9-437.2268.2
Cash Flow From Operating Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Net Income30.9482.02,680.61,657.8445.41,719.0307.0249.0640.02,702.0
Depreciation & Amortization0.018.0101.4108.713.0112.014.013.0174.022.0
Stock-Based Compensation0.034.0209.1169.920.5186.027.024.0153.0162.0
Change Working Capital253.22.0-665.4509.616.0-524.0-100.061.0158.0-137.0
Change In Accounts Receivable-41.9-47.0-1,273.7842.5-22.0-285.0-190.039.0797.00.0
Change In Accounts Payable299.10.00.00.00.00.00.00.0-740.00.0
Change In Inventories-4.0-1.0-6.3-20.41.2-34.010.0-7.0-57.00.0
Other Non-cash Items16.20.0-1,932.8-496.0-168.4540.0-29.0-128.0874.0-528.0
Cash from Operations0.00.00.00.00.00.00.00.01,672.02,037.0
Cash Flow From Investing Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Capital Expenditure-220.0-55.0-187.0-376.0-317.0-252.0-307.0-111.0-477.4-88.5-33.1-135.4-75.4-10.4-9.0-7.2-10.1
Acquisitions-12,977.0-7,220.7-12,246.00.00.00.00.032.0405.70.020.9125.963.32.70.00.00.0
Investments-9,050.0-995.8-8,636.0-10,907.0-9,698.0-15,616.0-12,414.0-5,812.0-3,521.2-3,425.0-3,008.5-2,075.5-2,679.3-974.3-1,775.5-1,090.0-1,585.0
Sales of Investment11,948.02,624.111,279.010,001.07,254.014,907.010,370.03,940.02,221.02,846.02,027.11,730.01,744.0999.11,367.51,611.3855.2
Other Investing Activities-761.00.00.00.00.00.00.0-32.0-405.70.0-20.9-125.9-63.249.80.60.61.4
Cash from Investing-9,647.00.00.0-1,282.0-2,761.0-961.0-2,351.0-1,983.0-1,777.6-667.6-1,014.5-480.9-1,010.767.0-416.3514.8-738.5
Cash Flow From Investing Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Capital Expenditure-13.0-2.0-63.4-81.5-12.2-38.0-4.0-4.0-67.0-98.0
Acquisitions-7,220.70.00.00.0125.70.00.00.0375.0-1,106.0
Investments-35.1-387.0-1,901.1-1,848.1-131.8-1,894.0-103.0-663.0-2,508.0-1,272.0
Sales of Investment1,692.4335.02,129.21,759.7147.12,087.0620.0457.02,133.02,378.0
Other Investing Activities0.00.00.00.00.00.00.00.0-375.01,106.0
Cash from Investing0.00.00.00.00.00.00.00.0-442.01,008.0
Cash Flow From Financing Activities TTM 2025202420232022202120202019201820172016201520142013201220112010
Debt Repaid-84.00.00.0-91.0-73.0-58.0-44.0-31.00.00.0-0.1-0.2-2.1-3.9-6.20.00.0
Debt Issued300.01,029.0259.0264.0245.0164.0182.0212.00.00.00.00.00.00.70.0-121.9133.7
Issuance of Common Stock124.00.00.00.00.00.00.03,873.00.30.80.82.6998.20.0366.40.00.0
Repurchase of Common Stock-3,595.0-430.3-3,988.0-564.0-908.0-447.00.00.0-146.20.0-118.10.00.00.00.00.00.0
Dividends Paid0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Other Financing Activities-63.00.00.049.0192.085.0115.0-182.075.0214.1208.6640.839.3155.6-2.4-6.1-7.0
Cash from Financing-3,648.00.00.0-606.0-789.0-420.071.03,660.0-70.9214.991.2643.11,035.4151.7357.8-6.1-7.0
Cash Flow From Financing Activities 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Debt Repaid0.00.00.00.00.00.00.00.0-25.00.0
Debt Issued0.0940.7-47.0-41.342.0-32.09.0240.02.0-10.0
Issuance of Common Stock0.00.00.00.00.00.00.00.09.040.0
Repurchase of Common Stock0.4-24.0-2,572.8-562.539.8-294.0-438.0-79.0-6.0-4.0
Dividends Paid0.00.00.00.00.00.00.00.00.00.0
Other Financing Activities0.00.00.00.00.00.00.00.03.020.0
Cash from Financing0.00.00.00.00.00.00.00.0-22.020.0
Cash position TTM 2025202420232022202120202019201820172016201520142013201220112010
Net Change in Cash-6,543.0345.3-5,009.04,974.0936.01,697.03,708.03,019.0-814.61,040.5-567.0514.9191.089.19.671.5-466.5
Closing Cash Balance4,331.01,711.19,858.014,867.09,893.08,957.07,260.03,552.0532.91,347.5307.0874.0359.1168.179.069.4-2.1
Cash position 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Net Change in Cash-45.9465.0-2,046.91,623.9425.42,011.0-1,505.0-77.0594.03,399.0
Closing Cash Balance1,711.11,761.08,212.811,000.11,375.46,342.0622.02,127.014,867.014,273.0
Free Cash Flow TTM 2025202420232022202120202019201820172016201520142013201220112010
Free Cash Flow6,515.01,149.97,584.07,004.03,595.01,976.06,126.01,215.0537.41,500.5294.6176.157.2-138.461.9-444.4258.1
Real Free Cash Flow5,851.01,149.96,863.06,418.03,156.01,666.05,926.01,068.0446.71,424.5241.4139.529.5-149.949.9-444.4258.1
Free Cash Flow 4-20253-20252-20251-20254-20243-20242-20241-20244-20233-2023
Free Cash Flow287.4534.0329.51,746.2299.51,985.0215.0215.01,605.01,939.0
Real Free Cash Flow287.4500.0120.41,576.3279.01,799.0188.0191.01,452.01,777.0
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní

Nacenění

Ukazatel Aktuální Historické Konkurence
P/E6.15.6-1.4
P/S22.29.4
P/B0.515.2
P/FCF6.88.4-1.5
Market cap$17.9$12.1
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.

Finance

Ukazatel Aktuální Historické Srovnání
Debt to Assets0 %1.2 %0 %
Debt to Income34.1 %3 %0 %
Debt to Free cash flow37.9 %7189.1 %0 %
Interest expense percentage3.4 %2.3 %0 %
Current ratio6.2 8.9 0

Efektivita

Ukazatel Aktuální Historické Srovnání
ROE8.2 %-0.8 %0 %
ROA6.7 %8 %0 %
CapEx to Revenue1.6 %4.2 %0 %
RaD to Revenue0 %48 %0 %
ROEM3,226,530.3 2623749.2

Marže

Ukazatel Aktuální Historické Srovnání
Gross margin93.2 %84.7 %0 %
Operating margin31.2 %22.5 %0 %
Net margin20.4 %10.4 %0 %

Dividenda

Ukazatel Aktuální Historické Srovnání
Dividend yield0 %0 %0 %
Dividend payout percentage0 %0 %0 %
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.

Ostatní

Ukazatel Aktuální Historické
Shares outstanding672.6 mil 554.3 mil
Employee count2.7 tis 1.5 tis

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Placený obsah

Pro přístup na tuto stránku budete potřebovat placené členství.

Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.

Akciový screener
Kalendář zisků
Super investoři
Porovnání akcií
preloader